In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Alto Neuroscience Inc (NYSE: ANRO) closed at $2.65 down -1.49% from its previous closing price of $2.69. In other words, the price has decreased by -$1.49 from its previous closing price. On the day, 0.62 million shares were traded. ANRO stock price reached its highest trading level at $2.82 during the session, while it also had its lowest trading level at $2.5784.
Ratios:
For a deeper understanding of Alto Neuroscience Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.92 and its Current Ratio is at 16.92. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on October 23, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $29 previously.
On September 03, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $29.Wedbush initiated its Outperform rating on September 03, 2024, with a $29 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 09 ’24 when Savitz Adam bought 12,069 shares for $12.60 per share. The transaction valued at 152,085 led to the insider holds 36,920 shares of the business.
Savitz Adam bought 2,931 shares of ANRO for $38,748 on Jul 10 ’24. The CHIEF MEDICAL OFFICER now owns 39,851 shares after completing the transaction at $13.22 per share. On Mar 28 ’24, another insider, Smith Nicholas Conrad, who serves as the CHIEF FINANCIAL OFFICER of the company, bought 6,150 shares for $16.36 each. As a result, the insider paid 100,628 and bolstered with 26,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANRO now has a Market Capitalization of 71471032 and an Enterprise Value of -94742056.
Stock Price History:
The Beta on a monthly basis for ANRO is 1.45, which has changed by -0.8408408 over the last 52 weeks, in comparison to a change of 0.086116076 over the same period for the S&P500. Over the past 52 weeks, ANRO has reached a high of $18.35, while it has fallen to a 52-week low of $2.63. The 50-Day Moving Average of the stock is -27.34%, while the 200-Day Moving Average is calculated to be -66.58%.
Shares Statistics:
For the past three months, ANRO has traded an average of 297.97K shares per day and 267930 over the past ten days. A total of 26.99M shares are outstanding, with a floating share count of 23.12M. Insiders hold about 14.61% of the company’s shares, while institutions hold 82.77% stake in the company. Shares short for ANRO as of 1740700800 were 3724631 with a Short Ratio of 12.50, compared to 1738281600 on 4048269. Therefore, it implies a Short% of Shares Outstanding of 3724631 and a Short% of Float of 17.53.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
